# Anadrol

*Also known as: Oxymetholone, A50, Drol*

Potent oral mass builder; high water retention and significant hepatotoxicity.

## Overview

Anadrol (oxymetholone) is a potent oral 17-alpha-alkylated DHT derivative, originally introduced clinically for anemia and osteoporosis and now used for hereditary angioedema. Despite being a DHT derivative it has an unusual quirk: it aromatizes (weakly, via a non-standard pathway), which is why users report significant water retention and estrogenic effects. It binds the androgen receptor and drives erythropoiesis strongly, which is the basis for its mass-building reputation. Its 8-hour half-life supports once- or twice-daily oral dosing. The dominant harm-reduction concerns are hepatotoxicity (rated severe among the orals), dyslipidemia, and blood pressure, so liver enzymes, lipids, and hematocrit are the monitoring priorities. HPTA suppression is rapid and complete.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 0.3 days (7.9833312 hours)
- **Cmax:** 500 ng/dL
- **Tmax:** 0.1 days
- **Bioavailability:** 95%

## Dosing

- **Default dose:** 50 mg
- **Typical range:** 25–100 mg
- **Units:** ng/dL

## Harm reduction

- **Aromatizes:** Yes
- **DHT derivative:** Yes
- **Hepatotoxicity:** severe
- **Injection frequency:** Oral, 1–2×/day

## Detection time (anti-doping)

- **Window:** 21–42 days post-last-dose
- **Target metabolite:** 18-nor-17β-hydroxymethyl-17α-methyl-5α-androst-13-en-3α-ol
- **Assay:** GC-MS/MS
- **Notes:** Novel long-term metabolites detectable ≥14 days via GC-MS/MS. Earlier metabolites cleared within 5–7 days.

## Source

- **Label:** Oxymetholone PK study
- **URL:** https://www.academia.edu/74246708/Validation_of_the_determination_of_oxymetholone_in_human_plasma_analysis_using_gas_chromatography_mass_spectrometry_Application_to_pharmacokinetic_studies

---

**Canonical URL:** https://anabolicdex.com/compounds/anadrol
**Plot:** https://anabolicdex.com/plot?compound=anadrol